MT-7117
Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Phase 3Topline results presented at AAD2026
Key Facts
Indication
Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Phase
Phase 3
Status
Topline results presented at AAD2026
Company
About Mitsubishi Tanabe Pharma
Japanese pharmaceutical company developing innovative treatments for immunology, neuroscience, and metabolic disorders.
View full company profileTherapeutic Areas
Other Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Dersimelagon (MT-7117) | Tanabe Pharma America | Phase 3 |